Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: A real-world, single centre case series

Response rates in this group at week 16 are higher than those seen in phase III clinical trials, despite previous biologic exposure in all patients. While concomitant HS medication may play a role in this higher response rate, bimekizumab is an important treatment option for moderate-to-severe HS.